Targeting senescence as an anticancer therapy
L Bousset, J Gil - Molecular Oncology, 2022 - Wiley Online Library
Cellular senescence is a stress response elicited by different molecular insults. Senescence
results in cell cycle exit and is characterised by multiple phenotypic changes such as the …
results in cell cycle exit and is characterised by multiple phenotypic changes such as the …
[HTML][HTML] The biology behind combining PARP and androgen receptor inhibition for metastatic castration resistant prostate cancer
For about a decade, poly [ADP ribose] polymerases (PARP) inhibitors have been used
almost exclusively to treat tumors that are deficient in one of the BRCA genes. In advanced …
almost exclusively to treat tumors that are deficient in one of the BRCA genes. In advanced …
Triggering pyroptosis enhances the antitumor efficacy of PARP inhibitors in prostate cancer
Purpose PARP inhibitors have revolutionized the treatment landscape for advanced prostate
cancer (PCa) patients who harboring mutations in homologous recombination repair (HRR) …
cancer (PCa) patients who harboring mutations in homologous recombination repair (HRR) …
Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts
P Jin, X Li, Y Xia, H Li, X Li, ZY Yang, Z Wang… - Molecular Cancer …, 2023 - AACR
Therapy-induced senescence (TIS) is common in tumor cells treated with PARP inhibitors
(PARPis) and can serve as a promising target for improving PARPi efficacy. However …
(PARPis) and can serve as a promising target for improving PARPi efficacy. However …
Therapeutic resistance models and treatment sequencing in advanced prostate cancer
Simple Summary Castration-resistant prostate cancer (CRPC) treatments include next-
generation anti-androgen therapies (NGATs), taxane therapy, and PARP inhibitors (PARPi) …
generation anti-androgen therapies (NGATs), taxane therapy, and PARP inhibitors (PARPi) …
IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer
Olaparib is a pioneering PARP inhibitor (PARPi) approved for treating castration-resistant
prostate cancer (CRPC) tumors harboring DNA repair defects, but clinical resistance has …
prostate cancer (CRPC) tumors harboring DNA repair defects, but clinical resistance has …
Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients
G De Lazzari, A Opattova, S Arena - Journal of Experimental & Clinical …, 2024 - Springer
Over the last few decades, the incidence of urogenital cancers has exhibited diverse trends
influenced by screening programs and geographical variations. Among women, there has …
influenced by screening programs and geographical variations. Among women, there has …
Transcriptomic analysis of Paraoxonase 1 expression in hepatocellular carcinoma and its potential impact on tumor immunity
L Dong, C Dong, Y Yu, X Jiao, X Zhang… - Clinical and …, 2024 - Springer
Background Hepatocellular carcinoma (HCC) is characterized by a complex pathogenesis
that confers aggressive malignancy, leading to a lack of dependable biomarkers for …
that confers aggressive malignancy, leading to a lack of dependable biomarkers for …
PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Olaparib, a PARP inhibitor, is a targeted therapy used in treating various cancers, including
castration-resistant prostate cancer. Despite its efficacy, resistance to olaparib remains a …
castration-resistant prostate cancer. Despite its efficacy, resistance to olaparib remains a …
Combined inhibition of MDM2 and PARP lead to a synergistic anti-tumoral response in p53 wild-type rhabdomyosarcoma models
Targeting MDM2-p53 interaction to enhance p53 activity represents a promising antitumoral
strategy for p53 wild-type pediatric tumors, including soft-tissue sarcomas. However, results …
strategy for p53 wild-type pediatric tumors, including soft-tissue sarcomas. However, results …